Monon Bioventures receives nearly $400,000 to develop Purdue-discovered glioblastoma treatment

Monon Bioventures LLC has received a one-year, $398,314 Phase I Small Business Innovation Research, or SBIR, grant from the National Cancer Institute to demonstrate the feasibility of manufacturing a glioblastoma therapeutic created at the Purdue University College of Pharmacy.

Related Keywords

Purdue University ,Indiana ,United States ,Indianapolis ,Monon Bioventures ,Monon Bioventure ,Dave Wilhite ,Joe Trebley ,Steve Martin ,Us Services ,National Cancer Institute ,Purdue Research Foundation Office Of Technology Commercialization ,Association Of Public ,Department Of Industrial ,Purdue Research Foundation ,College Of Pharmacy ,Purdue University College Of Pharmacy ,Drug Administration ,Ipwatchdog Institute ,Purdue University Photo ,Phasei Small Business Innovation Research ,Convergence Center ,Indiana Center ,Small Business Innovation Research ,Purdue University College ,Sandro Matosevic ,Physical Pharmacy ,Biomedical Innovation ,Purdue Research Foundation Office ,Technology Commercialization ,World Report ,Discovery Park District ,Economic Prosperity Universities Award ,